Compare CRNX & BIPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | BIPC |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.6B |
| IPO Year | 2018 | 2019 |
| Metric | CRNX | BIPC |
|---|---|---|
| Price | $41.08 | $38.87 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 8 | 1 |
| Target Price | ★ $76.75 | $45.00 |
| AVG Volume (30 Days) | 968.2K | ★ 1.1M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $7.85 |
| Revenue Next Year | $184.67 | $5.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $34.18 |
| 52 Week High | $57.99 | $51.72 |
| Indicator | CRNX | BIPC |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 43.95 |
| Support Level | $39.88 | $38.35 |
| Resistance Level | $41.33 | $40.93 |
| Average True Range (ATR) | 1.52 | 1.38 |
| MACD | 0.27 | -0.11 |
| Stochastic Oscillator | 76.34 | 55.41 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom, United States, France, Switzerland, Singapore, China, Denmark, Hong Kong, Germany and Others.